The global pediatric vaccines market size is calculated at USD 66.41 billion in 2025 and is forecasted to reach around USD 111.43 billion by 2034, accelerating at a CAGR of 5.92% from 2025 to 2034. The North America pediatric vaccines market size surpassed USD 23.19 billion in 2024 and is expanding at a CAGR of 5.96% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Pediatric Vaccines Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Pediatric Vaccines Market, By Type
8.1.1 Monovalent
8.1.1.1. Market Revenue and Forecast
8.1.2. Multivalent
8.1.2.1. Market Revenue and Forecast
9.1. Pediatric Vaccines Market, By Technology
9.1.1. Live Attenuated Vaccines
9.1.1.1. Market Revenue and Forecast
9.1.2. Inactivated Vaccines
9.1.2.1. Market Revenue and Forecast
9.1.3. Toxoid Vaccines
9.1.3.1. Market Revenue and Forecast
9.1.4. Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
9.1.4.1. Market Revenue and Forecast
10.1. Pediatric Vaccines Market, By Indication
10.1.1. Varicella
10.1.1.1. Market Revenue and Forecast
10.1.2. Human Papilloma Virus
10.1.2.1. Market Revenue and Forecast
10.1.3. Measles, Mumps & Rubella
10.1.3.1. Market Revenue and Forecast
10.1.4. Meningococcal Disease
10.1.4.1. Market Revenue and Forecast
10.1.5. Pneumococcal Disease
10.1.5.1. Market Revenue and Forecast
10.1.6. Polio
10.1.6.1. Market Revenue and Forecast
10.1.7. Rotavirus
10.1.7.1. Market Revenue and Forecast
10.1.8. Diphtheria, Pertussis & Tetanus
10.1.8.1. Market Revenue and Forecast
10.1.9. Influenza
10.1.9.1. Market Revenue and Forecast
10.1.10. Other Indications
10.1.10.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, By Type
11.1.2. Market Revenue and Forecast, By Technology
11.1.3. Market Revenue and Forecast, By Indication
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, By Type
11.1.4.2. Market Revenue and Forecast, By Technology
11.1.4.3. Market Revenue and Forecast, By Indication
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, By Type
11.1.5.2. Market Revenue and Forecast, By Technology
11.1.5.3. Market Revenue and Forecast, By Indication
11.2. Europe
11.2.1. Market Revenue and Forecast, By Type
11.2.2. Market Revenue and Forecast, By Technology
11.2.3. Market Revenue and Forecast, By Indication
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, By Type
11.2.4.2. Market Revenue and Forecast, By Technology
11.2.4.3. Market Revenue and Forecast, By Indication
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, By Type
11.2.5.2. Market Revenue and Forecast, By Technology
11.2.5.3. Market Revenue and Forecast, By Indication
11.2.6. France
11.2.6.1. Market Revenue and Forecast, By Type
11.2.6.2. Market Revenue and Forecast, By Technology
11.2.6.3. Market Revenue and Forecast, By Indication
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, By Type
11.2.7.2. Market Revenue and Forecast, By Technology
11.2.7.3. Market Revenue and Forecast, By Indication
11.3. APAC
11.3.1. Market Revenue and Forecast, By Type
11.3.2. Market Revenue and Forecast, By Technology
11.3.3. Market Revenue and Forecast, By Indication
11.3.4. India
11.3.4.1. Market Revenue and Forecast, By Type
11.3.4.2. Market Revenue and Forecast, By Technology
11.3.4.3. Market Revenue and Forecast, By Indication
11.3.5. China
11.3.5.1. Market Revenue and Forecast, By Type
11.3.5.2. Market Revenue and Forecast, By Technology
11.3.5.3. Market Revenue and Forecast, By Indication
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, By Type
11.3.6.2. Market Revenue and Forecast, By Technology
11.3.6.3. Market Revenue and Forecast, By Indication
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, By Type
11.3.7.2. Market Revenue and Forecast, By Technology
11.3.7.3. Market Revenue and Forecast, By Indication
11.4. MEA
11.4.1. Market Revenue and Forecast, By Type
11.4.2. Market Revenue and Forecast, By Technology
11.4.3. Market Revenue and Forecast, By Indication
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, By Type
11.4.4.2. Market Revenue and Forecast, By Technology
11.4.4.3. Market Revenue and Forecast, By Indication
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, By Type
11.4.5.2. Market Revenue and Forecast, By Technology
11.4.5.3. Market Revenue and Forecast, By Indication
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, By Type
11.4.6.2. Market Revenue and Forecast, By Technology
11.4.6.3. Market Revenue and Forecast, By Indication
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, By Type
11.4.7.2. Market Revenue and Forecast, By Technology
11.4.7.3. Market Revenue and Forecast, By Indication
11.5. Latin America
11.5.1. Market Revenue and Forecast, By Type
11.5.2. Market Revenue and Forecast, By Technology
11.5.3. Market Revenue and Forecast, By Indication
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, By Type
11.5.4.2. Market Revenue and Forecast, By Technology
11.5.4.3. Market Revenue and Forecast, By Indication
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, By Type
11.5.5.2. Market Revenue and Forecast, By Technology
11.5.5.3. Market Revenue and Forecast, By Indication
12.1. Serum Institute of India Pvt. Ltd.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Sanofi Aventis
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. CSL Limited
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. AstraZeneca Plc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Merck & Co., Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. GlaxoSmithKline Plc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Pfizer Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Emergent BioSolutions Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Novavax, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Johnson & Johnson
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample